MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DISHMAN PHARMA - MYLAN (US)
DISHMAN PHARMA vs MYLAN (US) - Comparison Results
DISHMAN PHARMA Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 DISHMAN PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
MYLAN Dec-18 |
DISHMAN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 3,570 | - | |
| Low | Rs | 129 | 1,965 | - | |
| Sales per share (Unadj.) | Rs | 197.8 | 1,642.9 | - | |
| Earnings per share (Unadj.) | Rs | 21.2 | 44.6 | - | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 352.2 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 1,777.4 | - | |
| Shares outstanding (eoy) | m | 80.69 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 1.7 | 75.5% | |
| Avg P/E ratio | x | 11.9 | 62.0 | 19.1% | |
| P/CF ratio (eoy) | x | 7.2 | 7.9 | 92.2% | |
| Price / Book Value ratio | x | 1.4 | 1.6 | 89.8% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 1,424,069 | 1.4% | |
| No. of employees | `000 | 0.8 | 35.0 | 2.4% | |
| Total wages/salary | Rs m | 5,355 | 0 | - | |
| Avg. sales/employee | Rs Th | 19,252.7 | 24,151.1 | 79.7% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 655.8 | 314.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 845,288 | 1.9% | |
| Other income | Rs m | 265 | 0 | - | |
| Total revenues | Rs m | 16,226 | 845,288 | 1.9% | |
| Gross profit | Rs m | 4,103 | 218,729 | 1.9% | |
| Depreciation | Rs m | 1,091 | 158,271 | 0.7% | |
| Interest | Rs m | 944 | 40,655 | 2.3% | |
| Profit before tax | Rs m | 2,334 | 19,803 | 11.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 624 | -3,150 | -19.8% | |
| Profit after tax | Rs m | 1,711 | 22,953 | 7.5% | |
| Gross profit margin | % | 25.7 | 25.9 | 99.4% | |
| Effective tax rate | % | 26.7 | -15.9 | -168.0% | |
| Net profit margin | % | 10.7 | 2.7 | 394.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 472,008 | 2.3% | |
| Current liabilities | Rs m | 9,517 | 344,146 | 2.8% | |
| Net working cap to sales | % | 9.4 | 15.1 | 62.2% | |
| Current ratio | x | 1.2 | 1.4 | 84.4% | |
| Inventory Days | Days | 110 | 84 | 132.2% | |
| Debtors Days | Days | 35 | 93 | 37.3% | |
| Net fixed assets | Rs m | 16,304 | 163,972 | 9.9% | |
| Share capital | Rs m | 161 | 450 | 35.9% | |
| Net worth | Rs m | 14,516 | 914,447 | 1.6% | |
| Long term debt | Rs m | 4,189 | 986,982 | 0.4% | |
| Total assets | Rs m | 29,805 | 2,452,902 | 1.2% | |
| Interest coverage | x | 3.5 | 1.5 | 233.4% | |
| Debt to equity ratio | x | 0.3 | 1.1 | 26.7% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 155.4% | |
| Return on assets | % | 8.9 | 2.6 | 343.6% | |
| Return on equity | % | 11.8 | 2.5 | 469.6% | |
| Return on capital | % | 17.5 | 3.2 | 551.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 175,651 | 1.6% | |
| From Investments | Rs m | -1,529 | -90,792 | 1.7% | |
| From Financial Activity | Rs m | -941 | -81,828 | 1.2% | |
| Net Cashflow | Rs m | 316 | 1,455 | 21.7% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 75.01 Rs / USD
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare DISHMAN PHARMA With: SANOFI INDIA FRESENIUS KABI ONCO. ALKEM LABORATORIES FULFORD INDIA NEULAND LABS
Today's Market
Sensex Opens Marginally Higher; Infosys Dips 4% Post Q4 Results(09:30 am)
Asian share markets are trading on a negative note today following mixed cues from Wall Street.
Related Views On News
Most Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
An India Revival Stock I'm Bullish On... (Profit Hunter)
Apr 9, 2021This could take India to the position of 3rd largest economy.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
Why the Market Fell Yesterday (Fast Profits Daily)
Apr 6, 2021In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More
